Investment Rating - The report maintains a "Buy" rating for the company [1][2]. Core Viewpoints - The company achieved a revenue of 1.299 billion RMB in the first half of 2024, representing a year-on-year growth of 0.90%. The net profit attributable to shareholders was 416 million RMB, up 4.99% year-on-year [1]. - The traditional Chinese medicine segment saw significant growth, with revenue reaching 199 million RMB, a year-on-year increase of 20.17% [1]. - The company is focusing on enhancing its core competitiveness through strategic goals, innovation, and management improvements [1]. - The company has made advancements in cutting-edge technologies, including collaborations in the ADC platform and mRNA vaccine development [1]. Financial Performance Summary - For 2024, the company is projected to achieve a net profit of 1.073 billion RMB, with a growth rate of 27% [2]. - The earnings per share (EPS) for 2024-2026 are forecasted to be 0.64, 0.81, and 1.01 RMB, respectively, with corresponding price-to-earnings (P/E) ratios of 12, 10, and 8 times [2]. - The company’s revenue is expected to grow from 3.610 billion RMB in 2024 to 5.379 billion RMB in 2026, with growth rates of 25.99% and 21.65% respectively [5].

安徽安科生物工程（集团）股份有限公司 2024 年 6 月非经营性资金占用及其他关联资金往来情况汇总表 编制单位：安徽安科生物工程（集团）股份有限公司 单位：元 1 / 2 非经营性资金 占用 资金占用方名称 占用方与上市公 司的关联关系 上市公司核算 的会计科目 2024 年初占用 资金余额 2024 年 1-6 月占 用累计发生金额 (不含利息) 2024 年 1-6 月 占用资金的 利息(如有) 2024 年 1-6 月偿 还累计发生金额 2024年6月末 占用资金余 额 占用形成 原因 占用性 质 控股股东、实际 控制人及其附 属企业 - - - 小计 — — — - - - - 前控股股东、实 际控制人及其 附属企业 - - - 小计 — — — - - - - - 总计 — — — - - - - - | 其他关联资金 | | 往来方与上市公 | 上市公司核算 | 2024 年初往来 | 2024 年 1-6 | 月往 | 2024 年 | 1-6 月 | 2024 年 1-6 | 月偿 | 2024年6月末 | 往来形成 | 往来性 | | --- | --- | --- | --- | --- ...

Financial Performance - The company's operating revenue for the first half of 2024 was approximately ¥1.30 billion, an increase of 0.90% compared to the same period last year[12]. - Net profit attributable to shareholders was approximately ¥416.13 million, reflecting a growth of 4.99% year-over-year[12]. - The net profit after deducting non-recurring gains and losses was approximately ¥390.20 million, up by 1.86% from the previous year[12]. - Basic and diluted earnings per share increased to ¥0.2482, representing a growth of 4.77%[12]. - Total assets at the end of the reporting period were approximately ¥4.84 billion, a decrease of 2.14% from the end of the previous year[12]. - The company's weighted average return on equity was 10.71%, down by 1.34% compared to the previous year[12]. - The total profit reached 492.02 million yuan, reflecting a year-on-year growth of 6.15%[28]. - The company achieved operating revenue of 1,298.82 million yuan, a year-on-year increase of 0.90%[28]. - The net cash flow from operating activities decreased by 38.18% to approximately ¥205.81 million[12]. - The company reported a total comprehensive income of ¥416,132,684.80 for the first half of 2024, reflecting a stable performance compared to the previous year[133]. Research and Development - The company is actively developing multiple new drug research projects, including monoclonal antibodies, bispecific antibodies, and innovative ADC drugs, to enhance its product pipeline[19]. - The company is committed to continuous R&D efforts, particularly in peptide-based therapies, to enhance its product pipeline and market competitiveness[24]. - The company is focused on expanding its market presence through strategic investments and collaborations, aiming for a robust growth trajectory[24]. - The company is advancing the construction of new production lines, including a 5000L fermentation tank for growth hormone, which is currently undergoing process validation[29]. - The company is actively pursuing clinical trials for multiple products, including the AK2017 injection and human interferon α2b spray, with several projects in various stages of development[30]. - The company is committed to deepening cooperation in the mRNA drug sector and is preparing for the launch of emerging gene therapy products[31]. - The company is exploring the development of new products and technologies to meet evolving market demands and improve patient outcomes[24]. - The company has a strong focus on R&D, with a well-established system and successful experience in the independent development and industrialization of multiple new drugs[37]. Corporate Governance and Compliance - The company has a comprehensive governance structure, including a board of directors and supervisory board, all of whom attended the meeting to review the semi-annual report[1]. - The company’s legal representative is Song Lihua, ensuring accountability for the accuracy of the financial report[7]. - The company emphasizes the importance of rational investment and risk awareness for investors regarding forward-looking statements[1]. - The company has not reported any changes in its registered address or contact information during the reporting period[9]. - The company maintains a commitment to transparency in its financial disclosures, with no changes in the locations for information disclosure during the reporting period[10]. - The company has not engaged in any significant related party transactions during the reporting period[92]. - The half-year financial report has not been audited, and there are no significant guarantees or major contracts reported[88][99]. Market and Industry Position - The biopharmaceutical industry is experiencing rapid growth, driven by strong demand and supportive government policies[16]. - The company is actively pursuing international expansion and innovation in biopharmaceuticals, aligning with national strategic initiatives[17]. - The company has been recognized with multiple national and provincial awards for its contributions to biotechnology and innovation[18]. - The company has positioned itself at the forefront of the biopharmaceutical industry, with its recombinant human growth hormone and interferon products leading in market share and brand advantage[37]. Environmental Responsibility - The company has invested over 28 million RMB in environmental governance and protection in the first half of 2024[84]. - The company has completed the environmental emergency response plan, which has been filed with the relevant environmental protection bureau, enhancing its emergency response capabilities[82]. - The company has reported zero instances of exceeding emission standards for wastewater and waste gas treatment facilities[81]. - The company has allocated approximately 146 million RMB for hazardous waste and wastewater treatment, as well as environmental protection equipment[82]. - Anke Biological achieved wastewater treatment compliance with COD at 84 mg/L, significantly below the standard of 350 mg/L, resulting in a reduction of 17.15 tons[78]. Shareholder and Capital Management - The company plans not to distribute cash dividends or issue bonus shares, nor will it increase capital through reserves[2]. - The company distributed a total cash dividend of ¥418,039,838.00 (including tax), accounting for 49.34% of the net profit attributable to shareholders for the year 2023[68]. - The company has maintained a continuous cash dividend for 15 years, with cumulative cash dividends exceeding 22.45 billion RMB, representing 63.27% of the net profit attributable to shareholders[84]. - The company’s major shareholders committed to not reducing their holdings for a period of six months starting from August 23, 2023[87]. - The company has a projected return of 21.41 million from a wealth management product with a duration of 70 days[54]. Strategic Initiatives - The company is focusing on improving operational efficiency and reducing production costs to adapt to the pressures of centralized procurement policies[63]. - The company is enhancing its investor relations management through multiple channels and platforms[68]. - The company is committed to continuous innovation and product development based on market demand and technological advancements[37]. - The company plans to focus on its core business and increase R&D investment to drive high-quality development[68]. - The company is actively advancing the construction of new facilities in the eastern region to meet market demand[68].

证券代码：300009 证券简称：安科生物 公告编号：2024-041 安徽安科生物工程（集团）股份有限公司 关于第八届监事会第十一次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）第八届监事 会第十一次会议于 2024 年 8 月 16 日以书面形式发出会议通知，2024 年 8 月 26 日上午 11:00 以现场会议的方式召开。应参会监事 3 人，实际参会监事 3 人。本 次会议的召开与表决程序符合《公司法》和《公司章程》等的有关规定，会议由 监事会主席李增礼先生主持。 经与会监事充分讨论，表决通过如下决议： 一、以 3 票赞成，0 票反对，0 票弃权审议通过了《<公司 2024 年半年度报 告>及其摘要》 公司监事会根据《证券法》第八十二条的规定和中国证监会、深圳证券交易 所有关规定的要求，对公司 2024 年半年度报告及其摘要进行了认真审核，并提 出如下书面审核意见： 经审核，监事会认为董事会编制和审核公司 2024 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容 ...

安徽天禾律师事务所 法律意见书 安徽天禾律师事务所 关于 安徽安科生物工程（集团）股份有限公司 第三期限制性股票激励计划 回购注销部分限制性股票相关事项 之 法律意见书 地址：安徽省合肥市怀宁路 288 号置地广场 A 座 34-35F 电话：（0551）62642792 传真：（0551）62620450 关于 安徽安科生物工程（集团）股份有限公司 第三期限制性股票激励计划 回购注销部分限制性股票相关事项 之 法律意见书 致：安徽安科生物工程（集团）股份有限公司 安徽天禾律师事务所（以下简称"本所"）接受安徽安科生物工程（集团） 股份有限公司（以下简称"安科生物"或"公司"）的委托，担任安科生物实 施第三期限制性股票激励计划相关事宜（以下简称"本次股权激励计划"或"激 励计划"）的专项法律顾问。本所律师根据《中华人民共和国公司法》（以下 简称《公司法》）《上市公司股权激励管理办法》（证监会 148 号令）（以下 简称《管理办法》）《深圳证券交易所创业板股票上市规则》（以下简称《上 市规则》）《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办 理》（以下简称《自律监管指南》）等有关法律及其他有关法 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 重要提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于2024年8 月26日召开第八届董事会第十二次会议审议通过了《关于回购注销部分限制性股 票的议案》，根据公司2022年第二次临时股东大会的授权，同意回购注销不符合 激励条件的公司第三期限制性股票激励计划（以下简称"第三期激励计划"）激 励对象已获授但尚未解除限售的全部限制性股票，本次回购注销限制性股票合计 1,951,800股，占公司现有股本总额的0.12%，其中：首次授予部分限制性股票回 购注销数量为1,873,800股，预留授予部分限制性股票回购注销数量为78,000股。 现就有关事项说明如下： 证券代码：300009 证券简称：安科生物 公告编号：2024-042 安徽安科生物工程（集团）股份有限公司 关于回购注销第三期限制性股票激励计划 部分限制性股票的公告 6、2022 年 9 月 19 日，公司第七届董事会第二十四次会议及第七届监事会 第二十一次会议审议通过的《关于向激励对象首次授予限制性股票的议案》，公 司独立董事对相关事项发表了同意 ...

经核查，同意公司根据《第三期限制性股票激励计划（草案修订稿）》的相 关规定，回购注销不再具备激励资格的激励对象已获授但尚未解除限售的全部限 制性股票。本次将以激励对象购买价格回购限制性股票并注销，其中：首次授予 部分回购价格为 4.81 元/股，回购注销的限制性股票数量为 1,873,800 股；预留授 予部分回购价格为 5.27 元/股，回购注销的限制性股票数量为 78,000 股，回购资 金为公司自有资金。本次回购注销完成后，公司第三期激励计划将继续按照法规 要求执行。 安徽安科生物工程（集团）股份有限公司 监事会 2024 年 8 月 26 日 核查意见 根据《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》等有关法 律、法规、规范性文件和《安徽安科生物工程（集团）股份有限公司章程》的规 定，安徽安科生物工程（集团）股份有限公司（以下简称"公司"）监事会于 2024 年 8 月 26 日召开第八届监事会第十一次会议，审议通过了《关于回购注销部分 限制性股票的议案》，对公司第三期限制性股票激励计划（以下简称"本次激励 计划" ...

证券代码：300009 证券简称：安科生物 公告编号：2024-037 安徽安科生物工程（集团）股份有限公司 关于全资子公司醋酸西曲瑞克原料药获得 上市申请批准通知书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 近日，安徽安科生物工程（集团）股份有限公司全资子公司上海苏豪逸明制 药有限公司（以下简称"苏豪逸明"）收到国家药品监督管理局签发的醋酸西曲 瑞克原料药《化学原料药上市申请批准通知书》，并在国家药品监督管理局药品 审评中心官方网站（http://www.cde.org.cn/）公示，与制剂共同审批结果为A，标 志着该原料药已具备国内市场准入资格。现将相关情况公告如下： 一、原料药登记信息及相关情况 1、通用名称：醋酸西曲瑞克 三、风险提示 产品的销售受市场环境等因素影响，具有不确定性，敬请广大投资者谨慎决 策，注意投资风险。 5、申请事项：境内生产化学原料药上市申请 6、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。 7、其他相关情况 醋酸西曲瑞克为合成十肽，是一种促性腺激素释放激素（GnRH ...